Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor‐ to dolutegravir‐based antiretroviral therapy: A prospective cohort study in Lesotho (DO‐REAL study)

Abstract

This is an open access article under the terms of the Creat ive Commo ns Attri butio n-NonCo mmerc ial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study

“…Early outcomes (16 weeks) in this group were good (98% had viral load <100 copies per mL), with high suppression also among the few with viraemia at TLD initiation (95%). 26 It is highly encouraging that our results uphold and expand upon these earlier findings.…”

“…‡Of 42 included, 36 were assessed at month 18, two were transferred out, three switched antiretroviral therapy following failure (two with dolutegravir drug resistance), and one lost to follow-up to the study (still in routine care). 25 To date, only one sub-Saharan African cohort (DO-REAL study) 26 reported on TLD transitioning with baseline viral load information. Early outcomes (16 weeks) in this group were good (98% had viral load <100 copies per mL), with high suppression also among the few with viraemia at TLD initiation (95%).…”

Brief Report: Virologic Impact of the Dolutegravir Transition: Prospective Results From the Multinational African Cohort Study

“… 1 Similarly, the DO-REAL study in Lesotho showed that among 44 participants with a VL above 100 copies/mL at transition, 42 (95%) dropped their VLs to below 100 copies/mL at follow-up. 14 These findings suggest that maintaining a tenofovir backbone rather than switching to zidovudine may be an appropriate option when switching to DTG-based therapy, allowing for continued 1 pill, once-a-day dosing and sparing the substantial adverse events associated with prolonged zidovudine therapy.…”

“…13 Similarly, a study in Lesotho showed that after switching to TLD, the proportion of participants with a VL , 100 copies/mL increased from 96% to 98%, and the percentage with pill count-based adherence .95% improved from 82% to 90%. 14 FIGURE 1. VL category by antiretroviral therapy switch status.…”

Determining the acceptability of point-of-care urine tenofovir testing and its performance in predicting HIV RNA suppression

“…A recent study assessing viral suppression in Lesotho after the initiative to transition to the use of TLD, revealed 98% suppression after regimen switch. 14 Thus, the generalizability of results from this study is limited to populations with similar prevalence of viral nonsuppression.…”